Major Milestone: RETeval Referenced in over 200 Publications

We are excited to announce that the device has been referenced in more than 200 publications. This achievement underscores the growing recognition of RETeval as a valuable aid in the diagnosis and management of retina and optic nerve diseases.
ERG Above and Beyond Retinal Imaging

A 7-year-old child was referred to confirm a multiple sclerosis (MS) diagnosis following a brain scan. The patient complained of visual changes but identifying the cause was complex due to limited patient cooperation. We obtained color fundus and OCT images, both of which appeared to be normal. A flash visual evoked potential (VEP) test was conducted at another clinical site, but the outcome was unreadable.
LKC Technologies, one of the Top 10 Ophthalmic Solution Providers – 2019

December 3, 2019 LKC Technologies has been named as one of the Top 10 Ophthalmic Solution Providers of 2019 by MedTech Outlook. We are delighted to share this exciting news and accept such recognition among many other ophthalmic solution providers shortlisted in this edition issued by MedTech Outlook. Click the button below to read the […]
My RETeval Experience – James Soque, Chief of Imaging

My RETeval Experience – James Soque, Chief of Imaging JAMES SOQUE November 8, 2019 Chief of Imaging, Island Retina – NY, USA Mr. Soque is a Certified Retinal Angiographer (CRA), Certified OCT technician (OCT-C)and a Certified Ophthalmic Assistant (COA). He assists in retinal surgery and serves on the Board of Education for the Ophthalmic Photographers’ […]
My RETeval Experience – Pamela Weber, MD

My RETeval Experience – Pamela Weber, MD November 7, 2019 PAMELA WEBER, MD General Ophthalmologist, Island Retina – NY, USA A graduate of McGill University, Montreal, Pamela Ann Weber, M.D. went on to Columbia University College of Physicians & Surgeons. Dr. Weber completed her Post-Doctoral training as a Resident in Ophthalmology at the New York […]
My RETevet Experience – Martí Cairó

My RETevet Experience – Martí Cairó MARTÍ CAIRÓ FONT October 24, 2019 Ophthalmologist, Hospital Veterinari Canis – Girona, Spain Dr. Cairó received his DVM from the Autonomous University of Barcelona in 2012 and performed a one-year rotating internship in 2013 at the same university. During 2014, while working as a general practitioner in Barcelona, he […]
My RETeval experience – Dara Khalatbari, MD

My RETeval experience – Dara Khalatbari, MD DARA KHALATBARI, MD October 22, 2019 General Ophthalmologist, Metrolina Eye Associates – North Carolina, USA Dr. Khalatbari operates at Union West Surgery Center in Indian Trail, NC; and The Surgery Center at Edgewater in Indian Land, SC. He has presented at numerous national meetings in ophthalmology and is […]
People with current major depression resemble healthy controls on flash Electroretinogram indices associated with impairment in people with stabilized schizophrenia

August 13, 2019 This publication featuring the RETeval device confirmed that people with schizophrenia have significantly different ERG responses than healthy controls, replicating the group’s earlier study. Further, sufferers of major depressive disorder can be differentiated from schizophrenia as their ERG responses are similar to healthy controls. Schizophrenia patients have significantly reduced amplitudes (see front […]
Longitudinal In Vivo Characterization of the Streptozotocin-Induced Diabetic Mouse Model: Focus on Early Inner Retinal Responses

March 5, 2019 The goal of this study was to perform an extensive temporal characterization of the early pathologic processes in the streptozotocin (STZ)–induced diabetic retinopathy (DR) mouse model, beyond the vascular phenotype, and to investigate the potential of clinically relevant compounds in attenuating these processes. READ FULL PUBLICATION
RETeval: Supernormal Flicker ERGs in Eyes With Central Retinal Vein Occlusion: Clinical Characteristics, Prognosis, and Effects of Anti-VEGF Agent

The purpose of the study was to determine the clinical characteristics, prognosis, and effect of anti-vascular endothelial growth factor (VEGF) agents on eyes with a central retinal vein occlusion (CRVO) with and without supernormal flicker ERG amplitudes. READ FULL PUBLICATION
